

21 November 2011

The Manager  
Company Announcements Office  
ASX Limited  
20 Bridge St  
SYDNEY NSW 2000

Dear Sir,

### **CORRECTION TO INVESTMENT PRESENTATION DATED 19 SEPTEMBER 2011**

On 19 September 2011, CBio lodged an updated investment presentation. Slide 15 of the presentation states: "\$3M - \$16M in upfront fees to be paid to CBio if option exercised". This is incorrect and, as is detailed in slide 32 of the presentation, should read: "\$3M - \$16M in upfront fees to be paid to CBio **if licence agreement executed**". CBio apologises for this error.

For and on behalf of the Board of CBio Limited

**ROSLYNN SHAND**  
Company Secretary

#### **About CBio Limited**

CBio is an Australian ASX listed company established in 2000. CBio's lead product XToll is a potential new-generation drug therapy which could provide safer and more effective treatment of autoimmune diseases such as rheumatoid arthritis (RA) and lupus. Global sales of RA therapies exceeded US\$17 billion in 2008. The global lupus market is expected to reach \$2.5 billion per annum by 2017. Novo Nordisk A/S, a top 20 global pharmaceutical company and world-leader in diabetes care, has an exclusive option to enter into a licence agreement for the intellectual property rights relating to XToll. XToll has been trialled in over 330 patients with no pattern of treatment-emergent serious adverse effects. The company's largest clinical trial to date completed in Q2 2011.

#### **Enquiries**

Melanie Farris  
Communications & Corporate Affairs Manager  
CBio Limited  
T: +61 (0)449 148 448  
melanie.farris@cbio.com.au